The usefulness of tumour markers in the diagnostics of head and neck cancer patients
Journal Title: Współczesna Onkologia - Year 2006, Vol 10, Issue 6
Abstract
The dominating histological type among head and neck tumours is squamous cell carcinoma. This creates specific preferences in choosing tumour markers determined for diagnosing head and neck cancer patients. Due to their limited usability, CEA determinations have not been employed in the biochemical diagnostics of this group of patients. For a long time, the squamous cell carcinoma antigen was considered to be a marker of choice in this respect. However, the relatively low sensibility and diagnostic specificity of the results of its determination, as well as low expression in poorly differentiated tumours, stimulate search for other markers. Large expectations are associated with the determination of CYFRA 21-1 which is a soluble fragment of cytokeratin 19. It has been shown that the frequency of its elevated levels depends on the clinical stage, histological differentiation, tumour size, nodal status and presence of distant metastases. The results of CYFRA 21-1 determinations are assumed to be of significant predictive and prognostic value. Aiming at increasing the efficiency of biochemical diagnostics in head and neck cancer patients, an analysis was made to find the usability of other markers and their biologically active substances, among others, sialic acid, ferritine, alpha-L-fucosidase, complementary in relation to SCC-Ag and/or CYFRA 21-1 determinations of these substances, allowing more thorough diagnostics of head and neck cancer patients.
Authors and Affiliations
Jan Kulpa, Ewa Wójcik, Urszula Rychlik
Keywords
Related Articles
- EP ID EP159829
- DOI -
- Views 68
- Downloads 0
Evaluation of efficiency of different radiotherapy methods for brain metastases in patients with lung cancer
Lung cancer is the first most malignant cancer in men and 1/3 of cases are morbid and mortal. Lung cancer in women is second after breast cancer. Brain metastases occur in 40% to 60% of all cases. Median survival in the...
Brachyterapia PDR (pulsacyjna) w leczeniu raka piersi
Leczenie oszczędzające raka piersi w skojarzeniu z uzupełniającą radioterapią jest coraz powszechniej stosowaną metodą leczenia wczesnego niezaawansowanego raka piersi. W większości przypadków leczenie polega na napromie...
Cancer procoagulant (CP) in surgical oncology diagnostics
A considerable advancement of the neoplastic process at the start of the treatment is one of the major reasons of high mortality caused by malignant neoplasms. Numerous studies have been devoted to the diagnosis of cance...
Niedokrwistość w przebiegu choroby nowotworowej – diagnostyka i leczenie
Niedokrwistość towarzysząca chorobie nowotworowej jest poważnym problemem klinicznym. Prawidłowa diagnostyka oparta na rozważeniu wszystkich możliwych przyczyn warunkuje skuteczne leczenie niedokrwistości, która pogars...
Brachyterapia HDR nowotworów skóry – doświadczenie Wielkopolskiego Centrum Onkologii
Cel pracy: Analizie poddano grupę chorych na nowotwór skóry leczonych metodą brachyterapii HDR. Materiał i metody: Od maja 1999 r. do maja 2004 r. leczono metodą brachyterapii HDR w Wielkopolskim Centrum Onkologii 179 c...